Papers of the Week

Depression is a widespread issue in the United States and the leading cause of disability globally, impacting people of all ages. Although selective serotonin reuptake inhibitors (SSRIs) are commonly used for treatment, they have limited effectiveness and may take weeks to show results. There is a pressing need for fast and effective solutions for various types of depression, including chronic, clinical, situational, and undiagnosed cases. Alternative interventions are necessary not only for diagnosed depression but also for enhancing creativity, mindfulness, sexual desire, and overall well-being in individuals without a medical diagnosis of depression. This Patent Highlight discloses compositions designed to reduce inflammation and improve or maintain mental and physical health. These compositions target issues like depression, pain, mood disorders, anxiety, PTSD, digestive problems, relaxation, focus, creativity, and aim to decrease reliance on pharmaceutical and illicit drugs. The compositions involve combinations of at least one 5-HT2A serotonin receptor agonist and one TRP receptor agonist, possibly including a TRP receptor antagonist.